publication venue for
- Safety Of The Pcsk9 Inhibitor Alirocumab: insights From 47,296 Patient-Years Of Observation. 2024
- Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis. 2023
- Cost-effectiveness of ticagrelor in patients with type 2 diabetes and coronary artery disease: a European economic evaluation of the THEMIS trial.. 8. 2022
- PCSK9 and inflammation: a review of experimental and clinical evidence. 2019